clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Infant, Premature, Diseases D007235 7 associated lipids
Parkinson Disease D010300 53 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Influenza, Human D007251 11 associated lipids
Lymphadenitis D008199 8 associated lipids
Drug Eruptions D003875 30 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Synovitis D013585 15 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Renal Insufficiency D051437 8 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Insulin Resistance D007333 99 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Bacteremia D016470 9 associated lipids
Hemophilia A D006467 10 associated lipids
Encephalitis D004660 15 associated lipids
Barrett Esophagus D001471 3 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Rosacea D012393 13 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Helicobacter Infections D016481 21 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Hand Dermatoses D006229 5 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Ergotism D004881 4 associated lipids
Ecchymosis D004438 3 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Dyspepsia D004415 5 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Giardiasis D005873 3 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Prurigo D011536 4 associated lipids
Chlamydia Infections D002690 7 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Whooping Cough D014917 6 associated lipids
Urethritis D014526 9 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Fistula D005402 8 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Confusion D003221 4 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Iris Diseases D007499 2 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ureteral Diseases D014515 3 associated lipids
IgA Deficiency D017098 2 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Soft Tissue Infections D018461 2 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Periodontal Abscess D010508 2 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Psittacosis D009956 4 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Mycetoma D008271 4 associated lipids
Diphtheria D004165 2 associated lipids
Empyema D004653 3 associated lipids
Rickettsia Infections D012282 5 associated lipids
Sporotrichosis D013174 3 associated lipids
Pleural Diseases D010995 4 associated lipids
Bartonella Infections D001474 3 associated lipids
Lymphangitis D008205 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Stjepanovic MI et al. Pulmonary and Vertebral Mycobacterium avium Disease in a HIV-negative 71-year-old Man - A Case Report. 2016 Infez Med pmid:28011973
Muñoz-Egea MC et al. Effect of Antibiotics and Antibiofilm Agents in the Ultrastructure and Development of Biofilms Developed by Nonpigmented Rapidly Growing Mycobacteria. 2016 Microb. Drug Resist. pmid:26208145
Salimi A et al. Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. 2016 Xenobiotica pmid:26068526
Campillo A et al. [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]. 2016 Gastroenterol Hepatol pmid:27084668
Chauffour A et al. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. 2016 PLoS Negl Trop Dis pmid:27755552
Abuhammour A et al. Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients. 2016 Arab J Gastroenterol pmid:27665525
Matsumoto H et al. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. 2016 Dig. Dis. Sci. pmid:27659671
Kasai C et al. Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. 2016 BMC Gastroenterol pmid:27716077
Gisbert JP Helicobacter pylori-related diseases. 2016 Gastroenterol Hepatol pmid:27888863
Rossi A et al. Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. 2016 Drug Dev Ind Pharm pmid:26065531
Christianson S et al. Time-to-Detection of Inducible Macrolide Resistance in Mycobacterium abscessus Subspecies and Its Association with the Erm(41) Sequevar. 2016 PLoS ONE pmid:27490181
Harada T et al. Premedication with Clarithromycin Is Effective against Secondary Bacterial Pneumonia during Influenza Virus Infection in a Pulmonary Emphysema Mouse Model. 2016 J. Pharmacol. Exp. Ther. pmid:27489022
Bonfigli AR et al. Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. 2016 Nutr Metab Cardiovasc Dis pmid:27480449
Orrin E et al. Sporotrichoid Mycobacterium chelonae. 2016 Australas. J. Dermatol. pmid:27469486
Yamamoto K et al. Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3. 2016 Pharmacol. Res. pmid:27468646
Ferro BE et al. Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. 2016 Antimicrob. Agents Chemother. pmid:27458221
Patton PH et al. Anti-tuberculous therapy for maintenance of remission in Crohn's disease. 2016 Cochrane Database Syst Rev pmid:27444319
Steurer J [Months of antibiotic therapy in persistent symptoms of Lyme disease without effect]. 2016 Praxis (Bern 1994) pmid:27269781
Chung JW et al. Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: A multicenter, prospective study. 2016 Dig Liver Dis pmid:27257049
Mitchell H and Katelaris P Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. 2016 Med. J. Aust. pmid:27256648
Ullah S et al. Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin. 2016 Drug Deliv pmid:27247018
Kuo CH et al. A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. 2016 Medicine (Baltimore) pmid:27227911
Sluch IM et al. Mycobacterium chelonae Scleral Abscess After Intravitreal Ranibizumab Injection. 2016 Cornea pmid:27227391
Parize P et al. Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts. 2016 J Eur Acad Dermatol Venereol pmid:25677464
Xu J et al. Preparation, characterization and pharmacokinetics evaluation of clarithromycin-loaded Eudragit(®) L-100 microspheres. 2016 Eur J Drug Metab Pharmacokinet pmid:25652786
Graham DY and Dore MP Helicobacter pylori therapy: a paradigm shift. 2016 Expert Rev Anti Infect Ther pmid:27077447
Song ZQ et al. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. 2016 Chin. Med. J. pmid:27064046
Matsumoto H et al. Molecular Detection of H. pylori Using Adherent Gastric Mucous to Biopsy Forceps. 2016 Helicobacter pmid:27061611
Tsaganos T et al. Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. 2016 Antimicrob. Agents Chemother. pmid:27044546
Buchicchio A et al. Biodegradation of carbamazepine and clarithromycin by Trichoderma harzianum and Pleurotus ostreatus investigated by liquid chromatography - high-resolution tandem mass spectrometry (FTICR MS-IRMPD). 2016 Sci. Total Environ. pmid:27039063
Melia MT and Auwaerter PG Time for a Different Approach to Lyme Disease and Long-Term Symptoms. 2016 N. Engl. J. Med. pmid:27028918
Berende A et al. Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. 2016 N. Engl. J. Med. pmid:27028911
D'Erme AM et al. Successful treatment of rosacea fulminans in a 59-year-old woman with macrolide antibiotics and prednisone. 2016 Int. J. Dermatol. pmid:27028670
Bakshi SS Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. 2016 J Laryngol Otol pmid:26878377
Franceschi F et al. High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylori infection. 2016 Eur Rev Med Pharmacol Sci pmid:26875899
Tepeš B et al. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. 2016 Eur J Gastroenterol Hepatol pmid:26862930
Lim SG et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. 2016 Dig Liver Dis pmid:26856963
Niv Y Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. 2016 Digestion pmid:26849820
Song Z et al. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. 2016 Dig Liver Dis pmid:26847964
Vermeer LM et al. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. 2016 Drug Metab. Dispos. pmid:26668209
Meng Y et al. Multi-functional Liposomes Enhancing Target and Antibacterial Immunity for Antimicrobial and Anti-Biofilm Against Methicillin-Resistant Staphylococcus aureus. 2016 Pharm. Res. pmid:26666773
Konstantinidis T et al. Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps. 2016 Antimicrob. Agents Chemother. pmid:26643338
Ferro BE et al. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. 2016 Antimicrob. Agents Chemother. pmid:26643335
Wu TS et al. Postcesarean section wound infection caused by Mycobacterium massiliense. 2016 J Microbiol Immunol Infect pmid:26350122
Kamiya K et al. Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. 2016 J. Dermatol. pmid:26508502
Mark TM and Coleman M It's Time to Take Clarithromycin Seriously in Multiple Myeloma. 2016 Acta Haematol. pmid:26505907
Qiu XH et al. Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells. 2016 Acta Haematol. pmid:26505646
Senatore FJ et al. Helicobacter pylori treatment: Still a work in progress. 2016 Postgrad Med pmid:26490697
Narita M et al. Antimicrobial Susceptibility of Microorganisms Isolated from Periapical Periodontitis Lesions. 2016 Bull. Tokyo Dent. Coll. pmid:27665691
Ghaith D et al. Mutations affecting domain V of the 23S rRNA gene in Helicobacter pylori from Cairo, Egypt. 2016 J Chemother pmid:26358218